GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Eargo Inc (NAS:EAR) » Definitions » Intrinsic Value: Projected FCF

Eargo (EAR) Intrinsic Value: Projected FCF : $0.00 (As of May. 03, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Eargo Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-03), Eargo's Intrinsic Value: Projected FCF is $0.00. The stock price of Eargo is $2.57. Therefore, Eargo's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Eargo's Intrinsic Value: Projected FCF or its related term are showing as below:

EAR's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.705
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Eargo Intrinsic Value: Projected FCF Historical Data

The historical data trend for Eargo's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eargo Intrinsic Value: Projected FCF Chart

Eargo Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

Eargo Quarterly Data
Dec17 Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Eargo's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Eargo's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eargo's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Eargo's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Eargo's Price-to-Projected-FCF falls into.



Eargo Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Eargo  (NAS:EAR) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Eargo's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=2.57/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eargo Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Eargo's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Eargo (EAR) Business Description

Traded in Other Exchanges
N/A
Address
2665 North First Street, Suite 300, San Jose, CA, USA, 95134
Eargo Inc is a medical device company, focused on improving the quality of life of people with hearing loss. The company offers hearing aids, professional support services, and other insurance-related services through a direct-to-consumer format with a personalized, consumer-centric approach. The product portfolio includes Eargo Neo HiFi, Eargo 5, Eargo 6, Eargo 7, and related accessories.
Executives
Mark Thorpe officer: Chief Accounting Officer C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
William Brownie officer: Chief Operating Officer C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Adam Laponis officer: Chief Financial Officer C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Christian Gormsen director, officer: President and CEO C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Trit Garg director C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Afshin Justin Sabet-peyman director C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Onkarr Narula director C/O PATIENT SQUARE EQUITY ADVISORS, LP, 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Donald J Spence director C/O OAKMONT ACQUISITION CORP., 33 BLOOMFIELD HILLS PARKWAY, SUITE 240, BLOOMFIELD HILLS MI 48304
Psc Echo Gp, Llc 10 percent owner 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Psc Echo, Lp 10 percent owner 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
David James Wu director 411 FIRST AVENUE SOUTH, SUITE 600, SEATTLE WA 98104
Nina Richardson director C/O SILICON LABORATORIES, 400 W CESAR CHAVEZ, AUSTIN TX 78701
Katie J Bayne director C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Geoff Pardo director 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Gilde Healthcare Holding B.v. 10 percent owner NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB